tbuckley/cabot-search huggingface dataset:
MIBI SPECT and Radioguided Surgery in the Accurate Location of a Posterior Mediastinal Parathyroid Adenoma
Authors: IGNACIO BANZO, FRANCISCO J. PENA, ROBERTO H. ALLENDE, REMEDIOS QUIRCE, JOSÉ M. CARRIL
Journal: Clinical Nuclear Medicine (2003)

MIBI SPECT accurately located an ectopic posterior mediastinal parathyroid adenoma in a woman with persistent hypercalcemia and elevated intact parathyroid hormone (PTH) levels after a left hemithyroidectomy and left inferior parathyroidectomy for primary hyperparathyroidism. Surgery was guided by gamma probe, and a parathyroid adenoma close to the right lateral aspect of the trachea and esophagus was removed.
Gifts to Physicians From Industry
Authors: Richard F. LeBlond
Journal: JAMA (1991)

<h3>To the Editor.</h3> —The Council on Ethical and Judicial Affairs of the AMA<sup>1</sup>has taken an important step toward clarifying the relationship between the medical service industry and physicians. Unfortunately, it is neglecting an important area of concern. Many university faculty members and prominent practicing physicians serve as paid consultants to major pharmaceutical houses and travel around the country giving seminars and educational conferences that are frequently, although not always, thinly veiled promotions for particular products. In doing so, they exercise their rights as individuals to contract for services, but they also abrogate their responsibilities as faculty members to pursue an impartial view of medical research and therapy. When they become agents of industry, they should be barred from serving on any major university or hospital committees that might cause a conflict of interest, such as pharmacy and therapeutics committees and committees that set standards of care or practice
Internet therapy
Authors: C. Crisci
Journal: BMJ (2001)

A C57BL/6 mouse transgenic for human MUC1 (MUC1.Tg) was developed to evaluate MUC1-specific tumor immunity in an animal that expresses MUC1 as a normal self protein. Previous studies showed that MUC1.Tg mice, challenged with syngeneic tumors expressing MUC1 (B16.MUC1), developed progressively growing MUC1-positive tumors, whereas wild-type C57BL/6 (wt) mice developed MUC1-negative tumors at a significantly slower rate. The results of a limiting dilution CTL frequency assay were not informative, in that similar numbers of MUC1-specific CTL precursors (CTL) were detected in MUC1.Tg and wt mice. Tumor immunity in vivo was characterized by an adoptive transfer method to evaluate the degree of MUC1 or non-MUC1 tumor immunity in wt or MUC1.Tg mice. The results revealed that wt mice developed protective tumor immunity mediated by MUC1-specific CD4<sup>+</sup> lymphocytes, while MUC1.Tg mice were functionally tolerant to MUC1 in vivo. The potential of adoptive immunotherapy to provide immunity to tumors expressing MUC1 and to produce undesirable autoimmunity in recipient MUC1.Tg mice expressing MUC1 as a self Ag was evaluated. Adoptive transfer of immune cells from wt mice primed in vivo with B16.MUC1 tumor cells into MUC1.Tg recipients resulted in significant increases in the survival of MUC1.Tg recipients compared with unmanipulated control MUC1.Tg mice challenged with B16.MUC1 tumor cells. This response was specific for MUC1 since control tumors developed at equivalent rates in recipient or control MUC1.Tg mice. No gross or histologic evidence of autoimmunity was observed in recipient MUC1.Tg mice, indicating that tumor immune responses mediated by MUC1-specific CD4<sup>+</sup> lymphocytes spare nontransformed epithelia-expressing MUC1.
Adeno-associated virus-mediated apo A-I milano genetherapy for atherosclerosis and restenosis Behrooz G. Sharifi, Kai-Gen Wu, Lai Wang, Tripiathi Rajavashsith, Sanjay Kaul, Prediman K. Shah. Cedars-Sinai Med. Ctr., Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
An Epidemiologic Study of Early Biologic Effects of Benzene in Chinese Workers
Authors: Nathaniel Rothman, Martyn T. Smith, Richard B. Hayes, Gui-Lin Li, Richard D. Irons, Mustafa Dosemeci, Robert Haas, Wayne S. Stillman, Martha Linet, Li-Qiang Xi, William E. Bechtold, Joseph Wiemels, Sharan Campleman, Luoping Zhang, Penelope J. E. Quintana, Nina Titenko-Holland, Yao-Zu Wang, Wei Lu, Prema Kolachana, Kathleen B. Meyer, Songnian Yin
Journal: Environmental Health Perspectives (1996)

Benzene is a recognized hematotoxin and leukemogen, but its mechanisms of action in humans are still uncertain.To provide insight into these processes, we carried out a cross-sectional study of 44 healthy workers currently exposed to benzene (median 8-hr time-weighted average; 31 ppm), and unexposed controls in Shanghai, China.Here we provide an overview of the study results on peripheral blood cell levels and somatic cell mutation frequency measured by the glycophorin A (GPA) gene loss assay and report on peripheral cytokine levels.All peripheral blood cell levels (i.e., total white blood cells, absolute lymphocyte count, platelets, red blood cells, and hemoglobin) were decreased among exposed workers compared to controls, with the exception of the red blood cell mean corpuscular volume, which was higher among exposed subjects.In contrast, peripheral cytokine levels (interleukin-3, interleukin-6, erythropoietin, granulocyte colony- stimulating factor, tissue necrosis factor-a) in a subset of the most highly exposed workers (n = 11) were similar to values in controls (n = 11), suggesting that benzene does not affect these growth factor levels in peripheral blood.The GPA assay measures stem cell or precursor erythroid cell mutations expressed in peripheral red blood cells of MN heterozygous subjects, identifying NN variants, which result from loss of the GPA M allele and duplication of the N allele, and No variants, which arise from gene inactivation.The NN (but not NO) GPA variant cell frequency was elevated in the exposed workers compared with controls (mean ± SD, 13.9 ± 8.4 mutants per million cells versus 7.4 ± 5.2 per million cells, respectively; p=0.0002), suggesting that benzene produces gene-duplicating but not gene-inactivating mutations at the GPA locus in bone marrow cells of exposed humans.These findings, combined with ongoing analyses of benzene macromolecular adducts and chromosomal aberrations, will provide an opportunity to comprehensively evaluate a wide range of early biologic effects associated with benzene exposure in humans.
The Cyclopedia of Medicine
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A NEGLECTED SOURCE OF TYPHOID BACILLI.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Domestic Correspondence.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surrogacy of time to prgression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials.
Authors: Takeshi Terashima, Tatsuya Yamashita, Kuniaki Arai, Tadashi Toyama, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Journal: Journal of Clinical Oncology (2018)

403 Background: Time to progression (TTP) is widely used as the endpoint in early-phase trials for advanced hepatocellular carcinoma (HCC). However, the relevance of using TTP as a surrogate marker for overall survival (OS) in pivotal trials remains uncertain. Methods: The PubMed database and ASCO meeting library were searched for reports of randomized controlled trials that investigated patients with advanced HCC, included data for both OS and TTP, and were launched between 2009 and 2016. Correlation between hazard ratios (HRs) for TTP and OS was determined using weighted linear regression. Correlations between median OS and TTP, and between median OS and post-progression survival (PPS), defined as the period obtained by subtracting median TTP from median OS, were also evaluated. Results: The database search yielded 24 trials with 50 arms. Overall, TTP HR correlated with OS HR (R = 0.73); however, the coefficient in the regression equation was 0.48. When trials were stratified by treatment line, TTP HR was more strongly correlated with OS HR in second-line (R = 0.91) than in first-line (R = 0.77) settings. Correlation between median OS and median TTP was weak (R = 0.50), whereas the correlation between median OS and median PPS was strong (R = 0.78). Conclusions: In advanced HCC, the OS HR can be predicted from the TTP HR, especially in second-line trials, which is useful when considering whether to proceed to a pivotal trial based on the results of early-phase trials. However, TTP may not be appropriate as a primary endpoint in a pivotal trial if the trial aims to evaluate the survival benefit of novel agents because improvement of TTP cannot fully reflect improvement of OS because of the impact of PPS on OS.
HIV Transmission Between Two Adolescent Brothers With Hemophilia
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts Pt.39
Authors: Enrique Herrera, Antonio Tejera, Ricardo Bosch, M Mendiola, A Ferna ´ndez, N Lopez, Darrell Rigel, Harold Rabinovitz, Robert Friedman, Andrew Affleck, Sheelagh Littlewood, Iain Leach
Journal: Journal of the American Academy of Dermatology (2006)
Vaccine requirements and recommendations for international travelers
Authors: J. Chin
Journal: JAMA (1982)

The incidence of infectious diseases preventable by vaccines is generally higher in foreign countries than in the United States. Thus, an increased risk of acquiring these diseases exists for US citizens traveling abroad. In addition, the importation of these infectious disease agents into the United States from both returning citizens and other international travelers is an ever-present threat. The increasing documentation of the importations of measles into the United States (p 2129) is a reflection of these problems. Requirements and recommendations for use of vaccines for travelers leaving the United States are based in part on their increased risk to these diseases during their foreign travel, but the primary purpose of international requirements is to prevent the international spread of diseases. This is the rationale behind the formulation of the International Health Regulations (IHR) pertaining to vaccination certificate requirements.<sup>1</sup>Unfortunately, many countries, including some that are signatories of and
Price Gouging?
Authors: Mike Mitka
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gaps in venereology.
Journal: BMJ (1971)

though enthusiasts have extended the procedure to patients with milder symptoms on the basis that subsequent myo- cardial infarction will be less likely to occur.Essential pre- requisites to the operation are a viable myocardium, evaluated by means of left ventricular angiography; a patent distal segment of artery; and accurate delineation of blocked or severely obstructed coronary arteries by high quality coronary arteriography.Early results are encouraging.Favaloro reports from the Cleveland Clinic over a thousand saphenous vein bypass
Workshop to Identify Critical Windows of Exposure for Children's Health: Immune and Respiratory Systems Work Group Summary
Authors: Rodney R. Dietert, Ruth A. Etzel, David Chen, Marilyn Halonen, Steven D. Holladay, Annie M. Jarabek, Kenneth Landreth, David B. Peden, Kent Pinkerton, Ralph J. Smialowicz, Tracey Zoetis
Journal: Environmental Health Perspectives (2000)
Section 55.—Juvenile Osteochondroses
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tests to Detect Asymptomatic Urinary Tract Infections
Authors: Louis L. Keeler
Journal: JAMA (1994)

<h3>To the Editor.</h3> —I was pleased to see the article by Bachman et al<sup>1</sup>regarding the various tests to detect asymptomatic urinary tract infections (AUTIs). I have long been a proponent of Gram's stain of the spun urinary sediment as the prime method for diagnosing UTI. It is inexpensive and fast and can be done in the office as part of the office visit. It saves the health care system a lot of money, and I am suspicious that this is the reason that it has not succeeded. There is little need for performing urine cultures in the office. If Gram's stain of the spun urinary sediment is positive, the patient can be treated 98% of the time with an inexpensive drug such as trimethoprim in combination with a sulfa drug or nitrofurantoin, since practically all organisms seen in outpatients are easily treated. If Gram's stain of the spun
A phase I study of zoledronic acid and low dose cyclophosphamide in children with recurrent/refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study
Authors: H. V. Russell, S. Groshen, T. Ara, Y. DeClerck, M. Malkovsky, C. P. Reynolds, K. Matthay, S. M. Blaney
Journal: Journal of Clinical Oncology (2007)

9572 Background: Zoledronic acid (ZA), is a new generation, highly potent bisphosphonate that delays progression of bone metastases in adult malignancies. Bone metastases occur in 60% of children with advanced neuroblastoma. Pre-clinical studies demonstrated ZA with low dose chemotherapy delayed progression of osteolytic neuroblastoma lesions in a xenograft mouse model, prompting a phase I trial of ZA in neuroblastoma. Methods: Three dose levels of intravenous ZA (2, 3 or 4 mg/m 2 ) administered every 28 days were evaluated in combination with continuous daily oral cyclophosphamide (CTX) (25 mg/m 2 /day) in patients with recurrent/refractory neuroblastoma and cortical bone lesions. The primary objective was to determine a recommended dose of ZA for future trials. Serial blood and urine samples were collected for pharmacokinetics, markers of osteoclast activity, and immunologic assays. Results: 14 patients (9 male), median age 7.9 years (0.8 - 26.6 years), were enrolled at ZA dose levels 2 mg/m 2 (n=4), 3 mg/m 2 (n=3), and 4 mg/m 2 (n=7). To date, 13 patients are evaluable for toxicity. Thirty-nine cycles were administered with a median of 1 cycle per patient (range 1 - 12). Treatment was well tolerated; one DLT (Grade 3 hypophosphatemia) occurred at 4 mg/m 2 ZA. Other grade 3 or 4 toxicities attributable to the combination included hypocalcemia (n=2), elevated transaminases (n=2), neutropenia (n=2), anemia (n=1), lymphopenia (n=1), and hypokalemia (n=1). Hypocalcemia occurred in 69% of first cycles and 8% of subsequent cycles. There were no renal toxicities or dental complications. There have been 2 partial responses by MIBG (central review pending), 4 stable disease, and 7 progressive disease; one patient is too early for response. Pharmacokinetic and correlative biology study results are pending. Conclusions: ZA is well tolerated and had evidence of responses when given with low dose CTX to children with recurrent/refractory neuroblastoma. The recommended dose of ZA for subsequent study is 4 mg/m 2 . Future studies incorporating ZA into the regimen for children with NB and cortical bone lesions are planned. No significant financial relationships to disclose.
EORTC Symposium on Progress and Perspectives in Lung Cancer Treatment
Journal: JNCI Journal of the National Cancer Institute (1979)

EORTC Symposium on Progress and Perspectives in Lung Cancer Treatment Get access JNCI: Journal of the National Cancer Institute, Volume 62, Issue 2, February 1979, Page 437, https://doi.org/10.1093/jnci/62.2.437-b Published: 01 February 1979
Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double-blind, placebo-controlled study
Authors: P McCormick
Journal: Hepatology (1992)

The aim of this study was to determine the effects of the long-acting somatostatin analog, octreotide, on portal venous pressure and collateral blood flow in cirrhotic patients with portal hypertension during fasting and postprandial states. In a double-blind, placebo-controlled study, we investigated the effects of octreotide on the hepatic venous pressures and azygos blood flow of 21 patients before and after a standard liquid meal containing 40 gm of protein in 250 ml. Octreotide significantly reduced azygos blood flow from a mean of 499 ± 65 ml/min to a mean of 355 ± 47 ml/min (p < 0.01), but it had no effect on the hepatic venous pressure gradient. The hepatic venous pressure gradient of patients in the placebo group increased significantly, from a fasting mean of 16.4 ± 1.6 mm Hg to a mean of 20.0 ± 1.7 mm Hg 30 min after the meal (p < 0.01). In a second protocol hepatic venous pressures were measured in 20 patients at 30-min intervals for 2 hr after ingestion of the mixed meal. Again the placebo group showed a significant increase in the hepatic venous pressure gradient 30 min after the meal (20.4 ± 1.5 mm Hg vs. 18.2 ± 1.2 mm Hg; p < 0.05), but the group receiving octreotide showed no significant changes during the 2 hr of observation. We conclude that octreotide significantly reduces azygos blood flow, with little effect on portal venous pressure, and that it appears to inhibit postprandial increases in portal pressure in cirrhotic patients with portal hypertension. (HEPATOLOGY 1992;16:1180–1186.)